Pharmacogenetics and immunosuppressor drugs: Impact and clinical interest in tranplantation;Pharmacogénétique des médicaments immunosuppresseurs: Impact et intérêt clinique en transplantation

Annales Pharmaceutiques Francaises

Volumn 65, Issue 6, 2007, Pages 382-389

  Marquet, P ^a,b   Djebli, N ^a,b   Picard, N ^a,b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Cytochromes P450; Efflux transporters; Transplantation; UGT

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; CYTOCHROME P450; DNA; GLYCOPROTEIN P; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

CONCENTRATION RESPONSE; CONFERENCE PAPER; DNA POLYMORPHISM; DOSE TIME EFFECT RELATION; DRUG TARGETING; ENZYME METABOLISM; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOME ANALYSIS; GRAFT RECIPIENT; LIVER GRAFT; METABOLIC REGULATION; ORGAN TRANSPLANTATION; PHARMACOGENETICS;

EID: 37149056249     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4509(07)74197-4     Document Type: Conference Paper

References (35)

1. Min DI, Ellingrod VL, Marsh S, McLeod H CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26: 524-8.
2. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
3. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. T Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
4. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-5.
5. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471-8.
6. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603.
7. Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rerolle JP, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Therap 2006; 80: 51-60.
8. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26: 600-8.
9. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33: 139-46.
10. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14: 501-15.
11. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004; 32: 775-8.
12. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78: 351-61.
13. Djebli N, Picard N, Rérolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and co-medications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17: 321-30.
14. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80.
15. Miller DS, Fricker G, Drewe J. p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997; 282: 440-4.
16. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24: 400-4.
17. Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56: 78-83.
18. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-56.
19. Mai I, Stormer E, Goldammer M, Johne A, Kruger H, Budde K, et al. MDR1 haplotypes do not affect the steadystate pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003; 43: 1101-7.
20. Singh D, Alexander J, Owen A, Rustom R, Bone M, Hammad A, et al. Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation 2004; 77: 557-61.
21. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21-5.
22. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp Clin Transplant 2006; 4: 416-9.
23. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914-9.
24. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-7.
25. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451-7.
26. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-96.
27. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-83.
28. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9.
29. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977-84.
30. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002; 54: 1311-31.
31. Djebli N, Le Meur Y, Picard N, Szelag JC, Rousseau A, Marquet P. Influence of MRP2 (C-24T) SNP on MPA metabolic plasma ratios in renal transplant recipients. Abstract in: Ther Drug Monit 2005; 27: 246.
32. Moscoso-Solorzano G, Cotto E, Garcia M, Gomez E, Ortega F. Genetic variation in cyclophillin gene is associated with deleterious effects on renal allograft. Transplantation 2006; 82 (1 Suppl 2): 652-3.
33. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti B, Ekberg H, Spleiss O, et al. Association of three polymorphims with acute rejection after kiney transplantation: an exploratory pharmacogenetic analysis of a randomised center clinical trial (the CAESAR study). Transplantation 2006; 82 (1 Suppl 2): 410-1.
34. van Agteren M, van Schaik R, de Fijter H, Hartmann A, Schmidt J, Budde K, et al. Polymorphism in the uridine diphosphate (UDP)- glucuronosyltransferase (UGT) gene explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics. Transplantation 2006; 82 (1 Suppl 2): 478.
35. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004; 36: 2787-90.